Kendall Law Group Begins Investigation on Behalf of XenoPort, Inc. Shareholders

DALLAS--(BUSINESS WIRE)--Kendall Law Group announces that a class action law suit has been filed today in the United States District Court for the Northern District of California on behalf of investors that purchased XenoPort, Inc. (NASDAQ: XNPT) common stock between May 5, 2009 and February 17, 2010. If you wish to learn more about your rights as a shareholder you are encouraged to contact attorney Scott Kendall at 877-744-3728 or [e-mail].

The complaint charges XenoPort and certain of its officers and directors with violations of the Securities Exchange Act of 1934 regarding false and misleading statements made by XenoPort and certain officers and directors in connection with Horizant, a drug treatment for Restless Leg Syndrome. XNPT stock fell 66% to close at $6.67 on February 18, 2010 after it was revealed that the FDA was delaying approval of Horizant for a second time due to findings that the drug had caused pancreatic cancer cells to form in lab rats.

Kendall Law Group has the credentials and experience to pursue any type of complex securities litigation in the nation. The firm led by former federal judge Joe Kendall and former U.S. Attorney, is a national securities firm that represents shareholders when publicly traded companies violate the law. Shareholders who purchased XNPT common stock before or during the relevant period may have a claim against the company and are urged to contact attorney Scott Kendall for more information.